Interstitial Keratitis Treatments

Find Interstitial Keratitis Treatments

Experiencing the symptoms of Interstitial Keratitis (IK), such as increasing corneal clouding, light sensitivity (photophobia), and pain, can be deeply distressing. When the cornea the clear, front dome of the eye, becomes inflamed, it severely compromises vision and makes daily activities challenging. Interstitial Keratitis is a rare condition that affects the middle layer of the cornea (the stroma), often as a manifestation of a previous or underlying systemic disease, such as a prior infection or an autoimmune disorder.

Treatment is essential to resolve the inflammation quickly, minimize permanent scarring, and preserve vision. If the inflammation persists, the cornea can develop permanent clouding and ghost vessels, severely hindering sight. Because IK is often the eye component of a larger problem, effective treatment must address both the acute inflammation in the eye and the root cause throughout the body. Medication choices depend on the specific underlying condition identified by the doctor (Mayo Clinic, 2023).

Overview of treatment options for Interstitial Keratitis

The primary goals of treating Interstitial Keratitis are twofold: rapidly controlling the inflammation and treating the underlying systemic illness. The overall approach is aggressive medication therapy.

Medication is the standard first-line treatment for IK. The most powerful anti-inflammatory drugs are applied directly to the eye, sometimes for several months, to prevent scarring. For patients with residual scarring that severely limits vision after the inflammation has fully resolved, corneal transplant (keratoplasty) may be considered, but medication is always prioritized first. Treatment duration is typically long-term to ensure the inflammation does not rebound once medications are tapered.

Medications used for Interstitial Keratitis

The first and most critical class of drugs used for IK are Topical Corticosteroids. These powerful anti-inflammatory eye drops, such as prednisolone or dexamethasone, are used to rapidly reduce the swelling and infiltration of inflammatory cells into the corneal stroma. They are the most effective way to clear the clouding and alleviate pain.

Once the underlying cause is identified, specific systemic medications are prescribed to address the root problem:

  1. Antiviral Medications: If IK is related to a herpes virus (simplex or zoster), oral antiviral drugs, such as acyclovir or valacyclovir, are used to suppress the virus and prevent recurrence.
  2. Antibiotic Medications: If the condition is linked to a bacterial infection like congenital syphilis or Lyme disease, systemic antibiotics (such as penicillin or doxycycline) are necessary to eliminate the bacterial threat.
  3. Systemic Immunosuppressants: For bilateral IK linked to severe autoimmune disorders (like Cogan’s syndrome), doctors may prescribe oral or intravenous immunosuppressive agents, such as methotrexate or cyclosporine, to control the body-wide immune attack that is targeting the eye (American Academy of Ophthalmology, 2021).

How these medications work

Corticosteroids work by suppressing the immune system’s inflammatory response. They stop the migration of white blood cells into the cornea and block the release of inflammatory chemicals, which rapidly reduces corneal swelling and pain. This mechanism is crucial for minimizing the formation of permanent scar tissue that would block vision.

Antivirals and antibiotics work by eliminating the specific infectious agents that initially triggered the IK. By removing the trigger, the body is less likely to launch a sustained, damaging immune attack against the cornea. Systemic immunosuppressants modify the overall function of the immune system to interrupt the widespread autoimmune reaction that causes damage to various parts of the body, including the eyes and ears (National Eye Institute, 2022).

Side effects and safety considerations

While vital for saving vision, Topical Corticosteroids carry significant risks, particularly with long-term use. Major concerns are elevated intraocular pressure, risking glaucoma, and cataract development. Treatment demands frequent, close monitoring by an eye specialist.

Systemic drugs also have general side effects. Antivirals may cause nausea or headache. Immunosuppressants can harm liver and kidney function, necessitating regular blood tests. Crucially, topical steroids must not be used with active fungal or amebic eye infections, as they rapidly worsen these conditions. Patients should seek immediate medical help if pain worsens suddenly or vision rapidly declines.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Academy of Ophthalmology. https://www.aao.org
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Eye Institute. https://www.nei.nih.gov
  4. MedlinePlus. https://medlineplus.gov

Medications for Interstitial Keratitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Interstitial Keratitis.

Found 8 Approved Drugs for Interstitial Keratitis

Acyclovir

Brand Names
Avaclyr, Xerese, Zovirax

Acyclovir

Brand Names
Avaclyr, Xerese, Zovirax
AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus. AVACLYR (acyclovir ophthalmic ointment) 3%, a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated in the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.

Natacyn

Generic Name
Natamycin

Natacyn

Generic Name
Natamycin
NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.

CycloSPORINE

Brand Names
CEQUA, Gengraf, Neoral, Restasis, Restasis MultiDose, Sandimmune, Verkazia, VEVYE

CycloSPORINE

Brand Names
CEQUA, Gengraf, Neoral, Restasis, Restasis MultiDose, Sandimmune, Verkazia, VEVYE
CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). ( 1 ) CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye) ( 1 ).

Loteprednol Etabonate

Brand Names
Alrex, Eysuvis, Inveltys, Lotemax, Zylet

Loteprednol Etabonate

Brand Names
Alrex, Eysuvis, Inveltys, Lotemax, Zylet
ALREX ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

MethylPREDNISolone

Brand Names
Medrol, Solu-Medrol, Solu-Medrol MethylPREDNISolone

MethylPREDNISolone

Brand Names
Medrol, Solu-Medrol, Solu-Medrol MethylPREDNISolone
MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances